Rosetta Genomics Announces Poster Presentations at AACR Annual Meeting 2013

 Rosetta Genomics Announces Poster Presentations at AACR Annual Meeting 2013

microRNA-based diagnostic assays for classifying renal cell tumors and for
classifying tumors from patients with cancer of unknown or uncertain primary
to be featured in poster session on April 7

PR Newswire

PHILADELPHIA and REHOVOT, Israel, April 2, 2013

PHILADELPHIA and REHOVOT, Israel, April 2, 2013 /PRNewswire/ -- Rosetta
Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of
microRNA-based molecular diagnostics, announces that two posters related to
the Company's microRNA-based diagnostic assays will be featured at the
American Association for Cancer Research (AACR) Annual Meeting 2013, to be
held April 6-10 at the Walter E. Washington Convention Center in Washington,
D.C. Both posters will be presented by Mats Sanden, M.D., Medical &
Laboratory Director, Rosetta Genomics and will be available for viewing
Sunday, April 7 from 1:00-5:00 p.m. local time in the Molecular and Cellular
Biology 12 Session in Hall A-C, Poster Section 34. The two posters are as

Title: "Development and validation of a microRNA-based diagnostic assay for
the classification of renal cell tumors"
Abstract number: 802
Summary: This poster describes the development and validation of the miRview^®
kidney assay, which differentiates between the four main types of primary
kidney tumors. The assay was developed on a microarray platform using 181
training samples and validated blindly on an independent set of 201 samples.
The assay was able to return results for 92% of the validation samples, with
95% accuracy.

Title: "A novel microRNA-based test demonstrates 92% accuracy in the
classification of metastatic tumors from patients diagnosed with carcinoma of
unknown primary"
Abstract number: 816
Summary: This study reports the performance and clinical utility of miRview^®
mets^2, a microRNA-based molecular diagnostic assay for identifying the tissue
of origin in real cases of cancer of unknown or uncertain primary (CUP)
patients collected by leading academic centers in Greece. The assay
demonstrated agreement in 92% of the cases with all pathological and clinical
information, including patient follow-up data. Results of this study
demonstrate the assay to be a helpful tool for identifying the correct final
clinical diagnosis and in facilitating the selection of optimal therapy,
including targeted agents, early in the disease course.

"Attendees at the prestigious AACR annual meeting are an important audience
for Rosetta Genomics, and we are delighted that studies involving our
microRNA-based diagnostic assays in kidney cancer and cancer of unknown or
uncertain primary are being featured this year," said Kenneth A. Berlin,
President and Chief Executive Officer of Rosetta Genomics.

"The classification of tumors into subtypes of renal cell cancer (RCC) has
historically been less than definitive by histology, cytology and
immunohistochemistry, particularly in the growing context of smaller,
non-resection derived diagnostic specimens. Expanded clarity of RCC diagnosis
through the availability of the miRview^® kidney assay will help lead to
improved rationalization and optimization of therapies both new and emerging,"
said Bob Wassman, M.D., Chief Medical Officer of Rosetta Genomics.

Regarding the second poster on CUP diagnosis by Rosetta's proprietary
microRNA-based miRview^® mets^2 assay, he added, "Where clinical and
immunohistochemical data are available, but uncertain, the resulting molecular
diagnoses from our assay will generally fall within the range of possible
cancers but more precisely and with no subjectivity, and will, with much
higher confidence, identify one tumor type. There are also hallmark cases
where unusual tumors of origin have actually been found only after molecular
analysis, both of which are critical advances for these patients."

About miRview^® Testing Services

miRview^® assays are a series of microRNA-based diagnostic testing services
offered by Rosetta Genomics. miRview^® mets² accurately identifies the primary
tumor type in primary and metastatic cancer including cancer of unknown or
uncertain primary (CUP). miRview^® meso diagnoses mesothelioma, a cancer
connected to asbestos exposure. miRview^® lung accurately identifies the four
main subtypes of lung cancer using small amounts of tumor cells. miRview^®
kidney accurately classifies the four most common kidney tumors: clear cell
renal cell carcinoma (RCC), papillary RCC, chromophobe RCC and oncocytoma.
miRview^® assays are designed to provide objective diagnostic data; it is the
treating physician's responsibility to diagnose and administer the appropriate
treatment. In the U.S. alone, Rosetta Genomics estimates that 200,000
patients a year may benefit from the miRview^® mets² assay, 60,000 from
miRview^® meso, 65,000 from miRview^® kidney and 226,000 patients from
miRview^® lung. The Company's assays are offered directly by Rosetta Genomics
in the U.S., and through distributors around the world. For more information,
please visit Parties interested in ordering the test can
contact Rosetta Genomics at (215) 382-9000 ext. 309.

About Rosetta Genomics

Rosetta develops and commercializes a full range of microRNA-based molecular
diagnostics. Founded in 2000, Rosetta's integrative research platform
combining bioinformatics and state-of-the-art laboratory processes has led to
the discovery of hundreds of biologically validated novel human microRNAs.
Building on its strong patent position and proprietary platform technologies,
Rosetta is working on the application of these technologies in the development
and commercialization of a full range of microRNA-based diagnostic tools.
Rosetta's miRview® testing services are commercially available through its
Philadelphia-based CAP-accredited, CLIA-certified lab. Frost & Sullivan
recognized Rosetta Genomics with the 2012 North American Next Generation
Diagnostics Entrepreneurial Company of the Year Award.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta's future expectations,
plans and prospects, including without limitation, statements relating
toRosetta's development or commercialization of molecular diagnostics, the
market acceptance of Rosetta's miRview^®assays,particularly
miRview^®mets^2, Rosetta's capitalization of its microRNA platform, Rosetta's
patent positionand Rosetta's development of personalized medicine products
and servicesconstitute forward-looking statements for the purposes of the
safe harbor provisions under The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by these
forward-looking statements as a result of various important factors, including
those risks more fully discussed in the "Risk Factors" section of Rosetta's
Annual Report on Form 20-F for the year ended December 31, 2012as filed with
the SEC. In addition, any forward-looking statements represent Rosetta's views
only as of the date of this release and should not be relied upon as
representing its views as of any subsequent date. Rosetta does not assume any
obligation to update any forward-looking statements unless required by law.

Company Contact:
Rosetta Genomics
Ken Berlin, President & CEO
(215) 382-9000, ext. 326

Investor Contacts:
Anne Marie Fields
(212) 838-3777
Bruce Voss
(310) 691-7100

SOURCE Rosetta Genomics Ltd.
Press spacebar to pause and continue. Press esc to stop.